Differences between users’ and addiction medicine experts’ harm and benefit assessments of licit and illicit psychoactive drugs: Input for psychoeducation and legalization/restriction debates

Background: There is a lack of benefit/harm assessments of illicit and licit psychoactive substances performed by substance-dependent users in comparison to addiction medicine experts.

Methods: We extended the analyses of substance harm/benefit assessments of German addiction medicine experts (N = 101), in parts reported recently in this journal [doi.org/10.3389/fpsyt.2020.59219], by the perspectives of substance-addicted persons. The same questionnaire as used for the abovementioned “experts-study” was handed out to inpatient detoxification or rehab treatment seeking German substance-dependent adults (N = 117) for a subsequent structured interview about harms and benefits of 33 new and traditional psychoactive substances comprising also prescription drugs.

Results and discussion: Both, users and experts, ranked the traditional illicit psychoactive substances heroin, cocaine and amphetamines within the top overall harm level group. Synthetic cannabinoids, alcohol and benzodiazepine were in a subordinate top-harm level position. Both cohorts also ranked methadone, nicotine and cannabis within the midrange and buprenorphine as well as psychotropic mushrooms within the lowest harm level positions. Experiences with prescription drugs (including opioidergic analgesics and gabapentinoids), cathinones, GHB, methamphetamine and methylphenidate was not prevalent in our user population. The same applied to barbiturates, propofol, kratom, ayahuasca with nearly zero assessments for each substance. The most user-experiences (>50% per assessed substance) were reported with nicotine, cannabis, alcohol, cocaine, heroin, amphetamine and methadone (core group). The user’s overall harm ratings in terms of these psychoactive substances were similar to those of the experts with the exception of the methadone assessment which was rated by the experts to be significantly less harmful if compared with the users’ estimation (supposed “treatment bias” of experts). The users’ benefit ratings for the traditional illicit psychoactive substances, cannabis as well as for nicotine were significantly more positive in comparison to those of the experts (supposed “attraction bias” of users). Both, experts and users, ranked the harms arising from the use of alcohol or benzodiazepines (usually unregulated substances) higher than the harms caused by the use of methadone, cannabis or psychotropic mushrooms (regulated by most Western narcotic acts). Users attributed the most benefits to buprenorphine, methadone and cannabis. This might reflect a main limitation of the study as the data are from an user population comprising over 50% patients who sought detoxification-treatment of opiates where methadone and buprenorphine are usual transient medications (supposed “selection bias”).

Conclusion: This study addressed current trends of psychoactive substance abuse (e.g., synthetic cannabinoids, prescription drugs) and provides from both perspectives (that of the user and that of the addiction medicine experts) robust harm/benefit evaluations at least of a core group of psychoactive substances (traditional illicit psychoactive substances, cannabis, methadone, alcohol and nicotine). The results of this study can be valuable to the psychoeducation of substance-addicted individuals and to current restriction/legalization debates, especially in the Western-EU.

Introduction

Persons who are using psychoactive substances have a lot of motives in doing so besides medical-therapeutic reasons. Non-medical motives comprise, e.g., self-medication, recreational, mind-altering, spiritual, affect-regulating, relaxing, doping, cognition-enhancing or sleep-improving purposes. As a rule, those aims are perceived as “beneficial.” However, the most psychoactive substances are also “hijacking” the mesolimbic dopaminergic reward system as a biological condition sine qua non for burgeoning and maintaining addictive behavior (1–4). The rewarding vigor of an individual psychoactive substance, as well as its availability, the context cues and the user’s vulnerability are powerful predictors of a substance abuse and dependence (ICD-10, DSM-IV TR III) or substance use-disorder (SUD) (3–5). Severely affected persons are compulsively using multiple psychoactive substances for non-medical purposes, displaying substance misuse spiraling out of executive self-control (4, 5). They invest a lot of their lifetime to get these substances to maintain pleasant intoxication effects (e.g., feeling “high,” relaxed or energetic) and to avoid physical and behavioral withdrawal; in sum this often leads to personal and social depravation; and in the case of illicit psychoactive substance use, more probably to delinquent behavior and substance related deaths (3–5).

Nutt et al. developed a consensus-based rating instrument for assessing an individual psychoactive substance’s overall harm potential considering physical, psychological and social harms to users and others (6). Within the last 20 years, several ratings by experts in the area of addictive disorders were carried out in several Western European countries and Australia (1, 6–12). These rankings do not necessarily show congruence with legislative and law enforcement priorities in terms of regulation and control of substances, with alcohol being a classic example of dissonance between a high level of overall harm and low levels of governmental regulation (1, 6–13). Few expert rankings also included potential beneficial effects of psychoactive substances (9, 14); and only one study included several prescription drugs being currently debated to be addictive, such as Non-Steroidal Anti-Inflammatory drugs (NSAIDs) and gabapentinoids (GPTs) (1, 14).

As of September 2022, there are very few comparative rankings of perceived harms and benefits arising from the use of psychoactive substances, which have been carried out by substance users (15, 16). However, these are essential to understand the relevance of the experts’ rankings for naturalistic treatment conditions and psychoeducation approaches. Therefore, we conducted a cross-sectional study including adult Germans undergoing an inpatient drug detoxification or inpatient drug users’ rehabilitation treatment. The results from the users’ perspective were compared with the results of the ranking of German addiction medicine experts, which have been recently published (1, 14). Users’ and experts’ rankings were based upon data collected within 2016 to 2019 in Germany and therefore, should reflect some regional as well common trends, including the emergence of novel psychoactive substances, such as synthetic cannabinoids and cathinones (17, 18), see also Supplementary material 2.1), or the increasing misuse of gabapentinoids (1, 19) and further prescription analgesics (20). We hypothesize that also in our study the rankings of both, experts and users, were not congruent with the narcotics acts of Western nations, at least for the position of alcohol. Furthermore, the results might be of interest for current restriction debates (e.g., domestic and abroad for gabapentinoids and alcohol) or legalization debates (e.g., for cannabis or psychotropic mushrooms) (21–23).

Materials and methods

The present cross-sectional study comprised two consecutive steps (survey 1 and survey 2, see below), in which quantitative questionnaires were distributed for a structured interview among German adults affected by substance dependence (ICD-10) and being admitted either to inpatient detoxification treatment (Evangelisches Krankenhaus Castrop-Rauxel) or inpatient rehab treatment (salus Klinik Castrop-Rauxel). Both hospitals are located close to each other, within the metropolitan Ruhr Area (see Supplementary material 2.1), Germany. The concept of this study (spanning from March 2017 to January 2019, Supplementary Figure 2) is the similar to our previous study (surveys carried out from March 2016 to May 2018, Supplementary Figure 2), which included addiction medicine experts recruited at German addiction congresses and conferences (1, 14). The present study, in contrast, additionally includes users of psychoactive substances, in order to enable a comparison between users’ and experts’ perspectives. The final results are for each group are based on two surveys: the first collected harms and benefits ratings, using pre-defined categories, and the second survey collected relative weights of the criteria, in order to calculate overall harm ratings (Supplementary Figure 1).

Expert ratings

The results of the expert survey were reported elsewhere (1, 14). Inclusion criteria were: to be a physician who (i) was a specialist, i.e., had extra expertise in at least one medical specialty and (ii) had been working longer than 5 years in German hospitals in the area of substance use disorders (SUD) treatment. The first experts’ survey was conducted from March 2016 to September 2017 (Supplementary Figure 2) and assessed the average harm of 33 substances (Figure 1) in 5 dimensions (physical harm to users, psychological harm to users, social harm to users, physical and psychological harm to others, and social harm to others). As shown in Supplementary Figure 1, these dimensions were defined by 16 criteria, which have been validated in several studies of this type (6, 8, 12) (see Supplementary material 2: “Methods”). Overall harm to users and overall harm to others comprised three (physical, psychological, social) dimensions and two (physical & psychological, social) dimensions, respectively (for details see Supplementary Figure 1). The assessments were carried out using 5-point scales (from “not harmful” to “extremely harmful”). Furthermore, overall beneficial substance effects were rated per 3-point scales (“no/little”/“moderate”/“a lot”).

FIGURE 1

Figure 1. Number of ratings made by user cohort 1, per substance. The minimum number of ratings required for inclusion of a substance was determined as n = 20. Extended version in Supplementary Figure 15.

The expert cohort comprised 101 participants. The physicians were advised to decide for themselves whether to assess a substance or not, and they were instructed to estimate their professional experience (“no/little”/“moderate”/“a lot”) with each substance they had rated. This information was used to determine the validity of the ratings and to verify defined exclusion criteria. In this context, a substance with less than 60% ratings was excluded from further analysis. Thus, the substances ayahuasca, khat, and kratom had to be excluded from the experts’ harm and benefit evaluation (1, 14). The second experts’ survey (for determining the relative weight of each health and social harm dimension to calculate the overall harm of each assessed substance, see Supplementary Figure 1) was conducted from September 2017 to May 2018 by cohort 2 (Supplementary Figure 2), which were recruited from the emails to 40 heads of German substance addiction treatment centers. This survey was separate because the first survey was very comprehensive; and combining the two surveys was deemed likely to reduce the return rate of cohort 1. All 36 returned questionnaires could be included. We used the mean relative weight given by the 36 experts to each dimension for calculating the overall harm of each substance (Table 1).

TABLE 1

Table 1. Relative weights of harm dimensions, as determined by German addiction experts, patients, and EU experts.

User ratings

The same questionnaires which had been developed for the experts’ rating of substance-related overall harm and benefit were handed out to the users during their inpatient treatment period in preparation for a subsequent structured interview (by AK-K). The study was carried out in accordance with the guidelines of the Declaration of Helsinki and was approved by the local ethics committee of the medical faculty of the University of Duisburg-Essen, Essen, Germany. Data collection was from March 2017 to January 2019 (Supplementary Figure 2). All adult patients voluntarily admitted to the ward specialized for detoxification treatments (Evangelisches Krankenhaus Castrop-Rauxel) or to the substance addiction rehab ward of the salus Klinik Castrop-Rauxel during the study period were considered for inclusion.

Exclusion criteria were insufficient proficiency of the German language and cognitive impairment (Mini Mental State [MMST] < 25 points). Patents eligible for the study who had given informed consent were asked to complete a standardized interview dealing basic sociodemographic data, history of substance use, and assessments of he several psychoactive substances (first users’ survey).

Data collection for cohort 1 was stopped after 100 interviews had been completed. To achieve this sample size, 117 patients had to be screened. Of these, 6 refused to participate, 3 withdrew from the interview after having given informed consent, and 8 had a MMST level <25 points.

The second users’ survey for weighting the dimensions to determine the overall harm was conducted within the same pool of inpatients during the aforementioned study period (from November 2018 to January 2019, Supplementary Figure 2) and included the first 44 completed returns of the questionnaires (cohort 2) distributed in this context (Table 1).

Miscellaneous

The users’ and experts’ identity was kept anonymous with the exception of information about their age, gender, specialties (experts), years of professional experience (experts), years of work in secondary/tertiary care (experts) of SUD, and main focus of professional work (acute care or rehabilitation hospital, experts) as well as, addiction history (user), comorbidity, socio-biography (user), respectively (Table 1). Just as for the expert raters (1, 14) we used a ratio of 75:25% for user raters recruited from an acute (EVK Castrop-Rauxel) versus a rehab clinic (salus Klinik Castrop-Rauxel, see also Supplementary material 2.1).

Data analysis and statistics

We set a cut-off of n = 20 for the minimum number of users’ ratings required for a substance in order to be included in the further analysis. With a median standard deviation of about 0.8 for the mean total harm ratings, this cutoff value is associated with a 95% confidence interval around the mean of ±0.35 (which becomes smaller with larger subsample sizes). Below the cutoff were triptanes (0 ratings), barbiturates (0), khat (0), propofol (1), cathinones (1), NSAIDs (1), flupirtine (1), ayahuasca (2, kratom (3), GHB (3), Z-drugs (3), natural hallucinogenics (5), methamphetamine (6), methylphenydate (7), opioidergic analgesics (7), ketamine (9), codeine (11), tilidine/tramadol (11), crack (12), and gabapentinoids (13 ratings) (Supplementary Figure 15). Figure 1 shows the number of ratings per substance (above the cut-off-level) performed by user cohort 1. We also explored a “core group” of psychoactive substances with more than 50% user ratings and less than 50% “no/less user experience-ratings for stronger data validation (Figures 1, 2). A further sensitivity test was carried out by comparing the overall harm-results when the relative harm dimension weights of the EU-rating (Table 1) were used.

FIGURE 2

Figure 2. Users’ experience regarding the evaluated substances in cohort 1. The “core group” (defined by <50% “no/little”-experience data and >50% ratings per substance) comprised the substances nicotine, cannabis, cocaine, alcohol, heroin, methadone, and amphetamines. Extended version in Supplementary Figure 16.

Beyond descriptive statistics, group comparisons were carried out by using the Welch-corrected t-test or the Mann–Whitney U-test (SPSS version 27) Significance level was set at 0.01.

Results

Samples

The experts’ sample characterization is already reported elsewhere (1). The users’ sociodemographic sample characteristics are shown in Table 2 The most frequent substances for which detoxification was sought were opioids (57%: heroin, 47%; opiate replacement therapy/medication, 10%), cannabis (40%), cocaine (31%), benzodiazepines (24%), and alcohol (24%). More than one substance was indicated in 79% of participants. There was no patient who sought a detoxification treatment for prescription analgesics including gabapentinoids (24). Psychiatric or somatic comorbidity was described in 85% of all participants (mostly depression, 36%; hepatitis C, 27%; COPD, 20%).

TABLE 2

Table 2. User characteristics.

Average overall harm

The experts’ overall harm assessments were already reported elsewhere (1). The users’ ratings considering the 5 separate dimensions are shown in the Supplementary Figures 3-7). The overall harm potential of the traditional substances of abuse, i.e., heroin, cocaine and amphetamines, was assessed by the user group to be the strongest of all 13 evaluated substances (Figure 3). Synthetic cannabinoids, alcohol and benzodiazepines had subordinate positions in the top harm-level group. Ecstasy, methadone (preferred in Germany for maintenance therapy of opioid dependence), nicotine, LSD and cannabis had been placed into the midrange. Buprenorphine (in Germany also frequently used for maintenance therapy of opioid dependence) and psychotropic mushrooms fell into the lowest harm ranges (Figure 3).

FIGURE 3

Figure 3. Average overall harm of the evaluated 13 substances (mean values and standard deviations) as assessed by the user cohort 1 on a scale from 0 (“not harmful”) to 4 (“extremely harmful”), shown as harmful to users and harmful to others. The relative contribution of the 5 dimensions (Supplementary Figure 1; Table 1) had been weighted by user cohort 2. Especially valid were the ranks of the core group of substances: nicotine, cannabis, cocaine, alcohol, heroin, methadone, and amphetamines (see Data analysis and statistics). Supplementary Figure 17 shows also the results for the excluded substances.

Sensitivity analysis: Changes of the rank order by using the EU-weights?

Using the weights determined per an evaluation of Western EU addiction experts (Table 1) did not change the rank order of overall substance harms rated by the experts (1, 14) or by the users in the present study (Figure 4) in a relevant manner.

FIGURE 4

Figure 4. Mean (SD) of the overall harm of the 13 substances using the dimension-weights of the EU-rating (8) on a scale from 0 “not harmful” to 4 “extremely harmful”. Supplementary Figure 18 shows also the results for the excluded substances.

Validity of the users’ overall harm-assessments

Figure 5 demonstrates the relationship of the substance harm assessments and the users experience with the corresponding substances. There were no statistical significant differences between the “moderate” and “a lot of” (much) experiences and the average overall harm ratings of each corresponding substance (Figure 5).

FIGURE 5

Figure 5. Substance harm-assessments and level of the users’ experience with the corresponding substances. Displayed are substances with n > 5 assessments in each experience group. *p < 0.01. The underlying data are shown in Supplementary Table 1.

Differences between the user ratings of inpatients treated in an acute and rehab hospital?

Supplementary Figure 8 comprised all substances with more than 6 ratings per substance and setting. We found no statistic relevant differences between the overall harm ratings of the users treated in the acute detoxification unit and the rehab clinic.

Comparison between overall harm ratings of user and experts

Figure 6 shows this comparison; the underlying ratings considering the separate dimensions are presented in Supplementary Figures 9–13. Both, users and experts ranked traditional illicit psychoactive substances (heroin, crack/cocaine, and amphetamines) within top harm-level positions (Figure 6). The rankings of both groups were very similar. Explicitly, the average overall harm of cocaine, heroin, nicotine, cannabis and alcohol was assessed to be not significantly different between user and experts. However, there were a few exceptions: within the core group, methadone, benzodiazepines and amphetamines are assessed to be significantly more harmful by the users.

FIGURE 6

Figure 6. Comparison between users’ and experts’ average overall harm ratings. The relative contribution of the 5 dimensions (Supplementary Figure 1 and Supplementary Table 1) had been weighted by the cohorts 2 of the user and experts. See also Supplementary Figure 20, which demonstrates the rank order. Additionally, the Supplementary Figure 19 shows the ratings for the excluded substances. *p < 0.01. Gray areas indicate standard deviations for the subgroups.

Average overall benefit/utility

The experts’ overall benefit assessments are already reported elsewhere (14). Figure 7 shows the user assessments. The strongest benefits/utilities were attributed to methadone, buprenorphine, and cannabis by the users. Synthetic cannabinoids were rated to have the smallest benefits (Figure 7).

FIGURE 7

Figure 7. Distributions of benefits categories (cohort 1). The substances are ranked according to proportions of “no benefit” ratings. Supplementary Figure 21 shows also the ratings for the excluded substances.

Comparison between overall benefit ratings of users and experts

Figure 8 (proportion of “strong benefit” ratings) and Supplementary Figure 14 (proportion of “no”/”little benefit” ratings) show this comparison. Within the core group, amphetamines, cocaine, heroin, nicotine and cannabis are assessed to be significantly more beneficial by the users. The average overall benefit rating of methadone and alcohol was not significantly different between user and experts. Beyond the core group, further substances were rated to be significantly more beneficial in comparison to the experts: ecstasy, LSD and psychotropic mushrooms.

FIGURE 8

Figure 8. Proportion of “strong benefit” ratings made by users versus experts. *p < 0.01. Supplementary Figure 23 shows also the ratings for the excluded substances.

Comparison of the overall harm/benefit rating-relations between user and experts

Figure 9 shows these relations. This figure uncovers that the users did not rank any substance in the category with strong harms and less benefits (square top right in this figure). Experts ranked methadone and prescription drugs (opioid analgesics, benzodiazepines, gabapentinoids) to be more beneficial in comparison to users.

FIGURE 9

Figure 9. Scatterplot of the users’ and experts’ overall substance harm/benefit ratios. The underlying data are shown in Supplementary Table 2. The users’ cannabis rating point is masked by the users’ LSD rating point. The experts’ nicotine rating point is masked by the experts’ psychotropic mushrooms rating point.

Discussion

To our knowledge, this is one of the first studies (16) comparing the harms and benefits of various psychoactive substances between the assessments of user and experts. Both cohorts ranked the traditional illicit psychoactive substances heroin, cocaine and amphetamines within the top overall harm level group. Synthetic cannabinoids, alcohol and benzodiazepine were in a subordinate top-harm level position. Both, users and experts, ranked methadone, nicotine and cannabis within the midrange and buprenorphine and psychotropic mushrooms within the lowest harm level positions. The Supplementary material shows that ketamine and gabapentinoids belong also to this category; unfortunately the ratings for these substances were below the cut-off of 20 ratings per substance. However, these results might be of interest for current restriction debates according to gabapentinoids (19, 25). As found within previous studies (6, 8, 9, 12, 16), also in our study, the rankings were not congruent with the narcotics acts of Western nations, because both, users and experts, ranked the harms arising from the use of alcohol or benzodiazepines (usually unregulated substances) higher than the harms caused by the use of methadone, cannabis or psychotropic mushrooms, i.e., substances being regulated by most Western narcotics acts.

Comparison with previous studies

The “backbone” of this rank order is similar to those determined by the most previous substance harm ratings with the following most apparent exception: alcohol was assessed to hold the largest overall harm level according to a majority of expert studies (6, 8, 9, 12) as well as a comparative experts-versus-user study (16). The other available user study placed alcohol in a near, but subordinate position to traditional illicit psychoactive substances, which is in line with the present study, but gave cannabis the lowest harm level position (15), just as the other available user study (16). Most expert evaluations ranked cannabis in a midrange harm position posterior to nicotine/tobacco (6, 8, 9, 12), just as the present study. The user group of the present study assigned methadone and buprenorphine to produce the largest beneficial effects. This assessment differed from prior user evaluations which preferred alcohol, tobacco and cannabis (9, 15, 16). We assume, that this disagreement most likely resulted from the special features of our user population comprising over 50% patients who sought detoxification-treatment of opiates where methadone and buprenorphine are usual transient medications (selection bias).

Further experiences and biases

Non-medical use of prescription drugs was not prevalent in our adult population seeking drug detoxification treatment. The same applied to barbiturates, propofol, kratom, ayahuasca with nearly zero assessments for each psychoactive substance. For non-opioidergic prescription drugs, the most user-experiences were reported for gabapentinoids (7%, see Supplementary Figure 16). 11, 9, and 6% of the patients reported experiences with tilidine/tramadol, codeine and opioidergic analgesics, respectively (Supplementary Figure 16). This relatively low experience level with opioidergic prescription drugs was in accordance with the situation in Germany, not suffering from an opioid epidemic which is contrasting with the situation in other Western nations (25–27). For the remaining substances, the most user-experiences (>50%) were reported with nicotine, cannabis, alcohol, cocaine, heroin, amphetamine and methadone (core group). The user’s overall harm ratings in terms of these core-group psychoactive substances were similar to those of the experts with the exception of the methadone assessment which was rated by the experts to be significantly less harmful if compared with the users’ estimation (availability bias by experts’ positive treatment and mortality-risk-reducing experiences with methadone in opioid addicts (28): “treatment bias”).

Notably, the users’ benefit ratings for the traditional illicit psychoactive substances heroin, cocaine, cannabis as well as for nicotine were significantly more positive in comparison with those of the experts. This phenomenon becomes especially obvious if we look at the missing user-assignments of substances in the category of substances with less benefit and great harm in Figure 9, which is clearly contrasting to the experts assessments. We assumed an underlying specific “user bias” resulting from a hedonic imbalance of the dopaminergic mesolimbic reward system (2) due to past addictive substance use experiences (“attraction bias”; resembling the “valence or hedonic tone bias” of emotions). This special bias of addicted persons might foster their substance craving and affective decision-making to relapse. In this regard, a large body of investigations supported a special implicit cognition of addicted persons, acquired by repetitive use of addictive substances or behaviors. Modern addiction theories are based upon this knowledge. In this context, it is hypothesized that repetitive rewarding/reinforcing substance use mediates (i) a sensitization of frontolimbic networks through which substance-related stimuli become emotionally/motivationally salient (attention bias; “attraction bias”) as well as (ii) an inhibition of cognitive control functions (both in the sense of addiction-related specific executive cognitive dysfunctions) (29–31). The modulation of these cognitive dysfunctions/biases is regarded as key challenge in the treatment of substance addiction (32).

Limitations and strengths

The representativeness of the users’ assessments is narrowed to a population of inpatient drug detoxification/rehab seeking adults of a Western German metropole region. The robustness of the experts’ and users’ overall harm rankings after stressing the results by sensitivity analyses (with EU-weights) might at least partially ameliorate this problem. Nonetheless, the compliance deficit of users (great portion of non-responses to substance-specific questions) and the corresponding exclusion of hazardous psychoactive substances, such as methamphetamine, which is considerably more stronger distributed, e.g., in the Eastern EU and Eastern provinces of Germany (1), consists to be a major limitation of this study. Similarly, users and experts from populations who are/were affected by an opioid epidemic most likely might assess the harm/benefit ratio of prescription opioids and gabapentinoids clearly greater than our participants residing in a region without opioid epidemic experiences (25), although about 50% of the participating users had wanted a detoxification of opioids (heroin and opioid maintenance medication). On the other hand, methadone and buprenorphine are common transient medications being used during these detoxification treatments, which can be considered as a further main limitation (selection bias). As this study addressed current trends of psychoactive substance abuse (e.g., synthetic cannabinoids, opioid analgesics, gabapentinoids) and provides robust evaluations at least of a core group of psychoactive substances comprising traditional illicit psychoactive substances, cannabis and nicotine, the results of this study can be valuable to the psychoeducation of addicted individuals and to current restriction/legalization debates. Furthermore, we found further evidence of a special bias (“attraction bias”) of substance-addicted persons in the self-evaluation of harms and benefits of psychoactive substance uses as well as a “treatment bias” of addiction medicine experts assessing harmful psychoactive substances, less harmful as they actually are, as becoming particularly apparent here in the case of methadone.

Conclusion

This study provides the assessments of users and addiction medicine experts with respect to the harms and benefits of various psychoactive substances, including traditional illicit psychoactive substances, cannabis, alcohol, and nicotine. Also, some modern psychoactive substance use trends related to synthetic cannabinoids and gabapentinoids (Supplementary material S5) were considered. Both, experts and users, ranked the harms arising from the use of alcohol or benzodiazepines (usually unregulated substances) higher than the harms arising from the use of methadone, cannabis or psychotropic mushrooms (regulated by most Western narcotic acts). Thus, also in our study the rankings were not congruent with the narcotics acts of Western nations (as we have hypothesized). The results could be valuable to the psychoeducation of addicted individuals and to current restriction/legalization debates, especially in the Western EU. Comparing the users’ and experts’ substance harm and benefit assessments pointed to a special bias of addicted persons (“attraction bias”) and a “treatment bias” of addiction medicine experts.

Data availability statement

The original contributions presented in this study are included in the article/Supplementary material, further inquiries can be directed to the corresponding author.

Ethics statement

The studies involving human participants were reviewed and approved by Medical Faculty of the University of Duisburg-Essen, Essen, Germany. The patients/participants provided their written informed consent to participate in this study.

Author contributions

UB: conception and design and drafting the manuscript. MS: analysis of the data. A-KK: collection of the data. All authors contributed to the interpretation of data and revising it critically for important intellectual content.

Acknowledgments

We cordially thank the patients and physicians who kindly took the time to participate in this project. Also, we cordially thank Jennifer Haverkemper, MSc (Psychology), for her assistance in developing the questionnaire for cohort 1. Furthermore, we acknowledge support from the Open Access Publication Fund of the University of Duisburg-Essen, Germany.

Conflict of interest

Author NS has received honoraria for several activities (e.g., advisory board membership, lectures, manuscripts) from AbbVie, Camurus, Hexal, Janssen-Cilag, MSD, Medice, Mundipharma, Reckitt-Benckiser/Indivior, and Sanofi-Aventis. During the last three years he has participated in clinical trials financed by the pharmaceutical industry.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpsyt.2022.1041762/full#supplementary-material

References

1. Bonnet U, Specka M, Soyka M, Alberti T, Bender S, Grigoleit T, et al. Ranking the harm of psychoactive drugs including prescription analgesics to users and others-a perspective of german addiction medicine experts. Front Psychiatry. (2020) 11:592199. doi: 10.3389/fpsyt.2020.592199

PubMed Abstract | CrossRef Full Text | Google Scholar

2. Gardner EL. Addiction and brain reward and antireward pathways. Adv Psychosom Med. (2011) 30:22–60. doi: 10.1159/000324065

PubMed Abstract | CrossRef Full Text | Google Scholar

3. Korpi ER, den Hollander B, Farooq U, Vashchinkina E, Rajkumar R, Nutt DJ, et al. Mechanisms of action and persistent neuroplasticity by drugs of abuse. Pharmacol Rev. (2015) 67:872–1004. doi: 10.1124/pr.115

CrossRef Full Text | Google Scholar

4. Heilig M, MacKillop J, Martinez D, Rehm J, Leggio L, Vanderschuren LJMJ. Addiction as a brain disease revised: why it still matters, and the need for consilience. Neuropsychopharmacology. (2021) 46:1715–23. doi: 10.1038/s41386-020-00950-y

PubMed Abstract | CrossRef Full Text | Google Scholar

5. Volkow ND, Wang GJ, Fowler JS, Tomasi D, Telang F. Addiction: beyond dopamine reward circuitry. Proc Natl Acad Sci USA. (2011) 108:15037–42. doi: 10.1073/pnas.1010654108

PubMed Abstract | CrossRef Full Text | Google Scholar

6. Nutt DJ, King LA, Phillips LD Independent Scientific Committee on Drugs. Drug harms in the UK: a multicriteria decision analysis. Lancet. (2010) 376:1558–65. doi: 10.1016/S0140-6736(10)61462-6

CrossRef Full Text | Google Scholar

7. van Amsterdam J, Opperhuizen A, Koeter M, van den Brink W. Ranking the harm of alcohol, tobacco and illicit drugs for the individual and the population. Eur Addict Res. (2010) 16:202–7. doi: 10.1159/000317249

PubMed Abstract | CrossRef Full Text | Google Scholar

8. van Amsterdam J, Nutt D, Phillips L, van den Brink W. European rating of drug harms. J Psychopharmacol. (2015) 29:655–60. doi: 10.1177/0269881115581980

PubMed Abstract | CrossRef Full Text | Google Scholar

9. Bourgain C, Falissard B, Blecha L, Benyamina A, Karila L, Reynaud M. A damage/benefit evaluation of addictive product use. Addiction. (2012) 107:441–50.

Google Scholar

10. Taylor M, Mackay K, Murphy J, McIntosh A, McIntosh C, Anderson S, et al. Quantifying the RR of harm to self and others from substance misuse: results froma survey of clinical experts across Scotland. BMJ Open. (2012) 2:e000774. doi: 10.1136/bmjopen-2011-000774

PubMed Abstract | CrossRef Full Text | Google Scholar

11. Lachenmeier DW, Rehm J. Comparative risk assessment of alcohol, tobacco, cannabis and other illicit drugs using the margin of exposure approach. Sci Rep. (2015) 5:8126. doi: 10.1038/srep08126

PubMed Abstract | CrossRef Full Text | Google Scholar

12. Bonomo Y, Norman A, Biondo S, Bruno R, Daglish M, Dawe S, et al. The Australian drug harms ranking study. J Psychopharmacol. (2019) 33:759–68. doi: 10.1177/0269881119841569

PubMed Abstract | CrossRef Full Text | Google Scholar

13. van Amsterdam J, Phillips L, Henderson G, Bell J, Bowden-Jones O, Hammersley R, et al. Ranking the harm of non-medically used prescription opioids in the UK. Regul Toxicol Pharmacol. (2015) 73:999–1004. doi: 10.1016/j.yrtph.2015.09.014

PubMed Abstract | CrossRef Full Text | Google Scholar

14. Bonnet U, Specka M, Soyka M, Alberti T, Bender S, Hilger J, et al. [Weighing the benefits and harms of psychotropic and analgesic substances - A perspective of German addiction medicine experts]. Fortschr Neurol Psychiatr. (2022) 90:19–29. doi: 10.1055/a-1363-0223

PubMed Abstract | CrossRef Full Text | Google Scholar

15. Morgan CJ, Noronha LA, Muetzelfeldt M, Feilding A, Curran HV. Harms and benefits associated with psychoactive drugs: findings of an international survey of active drug users. J Psychopharmacol. (2013) 27:497–506. doi: 10.1177/0269881113477744

PubMed Abstract | CrossRef Full Text | Google Scholar

16. Reynaud M, Luquiens A, Aubin HJ, Talon C, Bourgain C. Quantitative damage-benefit evaluation of drug effects: major discrepancies between the general population, users and experts. J Psychopharmacol. (2013) 27:590–9. doi: 10.1177/0269881113487809

PubMed Abstract | CrossRef Full Text | Google Scholar

17. Bonnet U, Mahler H. [Synthetic cannabinoids: spread, addiction biology & current perspective of personal health hazard]. Fortschr Neurol Psychiatr. (2015) 83:221–31. doi: 10.1055/s-0034-1399307

PubMed Abstract | CrossRef Full Text | Google Scholar

18. Scherbaum N, Schifano F, Bonnet U. New Psychoactive Substances (NPS) - a Challenge for the Addiction Treatment Services. Pharmacopsychiatry. (2017) 50:116–22. doi: 10.1055/s-0043-102059

PubMed Abstract | CrossRef Full Text | Google Scholar

19. Bonnet U, Scherbaum N. How addictive are gabapentin and pregabalin? A systematic review. Eur Neuropsychopharmacol. (2017) 27:1185–215. doi: 10.1016/j.euroneuro.2017.08.430

PubMed Abstract | CrossRef Full Text | Google Scholar

20. Bonnet U, Strasser JC, Scherbaum N. Screening for physical and behavioral dependence on non-opioid analgesics in a German elderly hospital population. Addict Behav. (2019) 90:265–71. doi: 10.1016/j.addbeh.2018.11.009

PubMed Abstract | CrossRef Full Text | Google Scholar

21. Isorna M, Pascual F, Aso E, Arias F. Impact of the legalisation of recreational cannabis use. Adicciones. (2022) 1694. doi: 10.20882/adicciones.1694 [Epub ahead of print].

PubMed Abstract | CrossRef Full Text | Google Scholar

22. Wodarz N, Hoch E, Driessen M, Gouzoulis-Mayfrank E, Batra A, Kiefer F, et al. Positionspapier der DGPPN. Cannabis-Legalisierung: Prävention und Jugendschutz sind nicht verhandelbar. NeuroTransmitter. (2022) 33:17–9. doi: 10.1007/s15016-022-9491-8

CrossRef Full Text | Google Scholar

23. Webster P. Denver votes to decriminalise psilocybin mushrooms. Lancet. (2019) 393:2023. doi: 10.1016/S0140-6736(19)31082-7

CrossRef Full Text | Google Scholar

24. Bonnet U, Kanti AK, Scherbaum N, Specka M. The role of gabapentinoids in the substance use pattern of adult germans seeking inpatient detoxification treatment - a pilot study. J Psychoact Drugs. (2022) 1–10. [Epub ahead of print].

Google Scholar

25. Bonnet U, Auwärter V, Scherbaum N. Gabapentinoid-related deaths: An alarming global trend or just a special challenge within the long tail of the giant opioid epidemic? Lancet Reg Health – Am. (2022) 11:100309. doi: 10.1016/j.lana.2022.100309

CrossRef Full Text | Google Scholar

26. Krausz RM, Westenberg JN, Ziafat K. The opioid overdose crisis as a global health challenge. Curr Opin Psychiatry (2021) 34:405–12. doi: 10.1097/YCO.0000000000000712

PubMed Abstract | CrossRef Full Text | Google Scholar

27. Häuser W, Buchser E, Finn DP, Dom G, Fors E, Heiskanen T, et al. Is Europe also facing an opioid crisis?-A survey of European Pain Federation chapters. Eur J Pain. (2021) 25:1760–9. doi: 10.1002/ejp.1786

PubMed Abstract | CrossRef Full Text | Google Scholar

28. Dematteis M, Auriacombe M, D’Agnone O, Somaini L, Szerman N, Littlewood R, et al. Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus. Expert Opin Pharmacother. (2017) 18:1987–99. doi: 10.1080/14656566.2017.1409722

PubMed Abstract | CrossRef Full Text | Google Scholar

29. Cox WM, Fadardi JS, Pothos EM. The addiction-stroop test: Theoretical considerations and procedural recommendations. Psychol Bull. (2006) 132:443–76. doi: 10.1037/0033-2909.132.3.443

PubMed Abstract | CrossRef Full Text | Google Scholar

30. Bühringer G, Wittchen HU, Gottlebe K, Kufeld C, Goschke T. Why people change? The role of cognitive-control processes in the onset and cessation of substance abuse disorders. Int J Methods Psychiatr Res. (2008) 17(Suppl 1):S4–15. doi: 10.1002/mpr.246

PubMed Abstract | CrossRef Full Text | Google Scholar

31. Berridge KC, Robinson TE. Liking, wanting, and the incentive-sensitization theory of addiction. Am Psychol. (2016) 71:670–9. doi: 10.1037/amp0000059

PubMed Abstract | CrossRef Full Text | Google Scholar

32. Christiansen P, Schoenmakers TM, Field M. Less than meets the eye: reappraising the clinical relevance of attentional bias in addiction. Addict Behav. (2015) 44:43–50. doi: 10.1016/j.addbeh.2014.10.005

PubMed Abstract | CrossRef Full Text | Google Scholar